The prescription weight loss market in 2026 is dominated by GLP-1 receptor agonists — but there are meaningful differences between options. Here's an objective breakdown of what the data actually shows.
The Medications
### Semaglutide (Ozempic/Wegovy/compounded) Mechanism: GLP-1 receptor agonist — slows gastric emptying, reduces appetite signals in the brain, improves insulin sensitivity
Clinical data: STEP trials showed average weight loss of 14.9% at 68 weeks at the 2.4mg/week dose. In absolute terms, patients averaging 230 lbs lost ~34 lbs.
Approved doses for weight loss: 0.25mg/week (starting) → 2.4mg/week (maintenance)
Timeline: Titration over ~16–20 weeks; full effect takes 9–12 months
Side effects: Nausea (40%), diarrhea (30%), vomiting (24%), constipation (24%) — mostly during titration. Serious: rare pancreatitis risk, gallbladder disease.
### Tirzepatide (Mounjaro/Zepbound/compounded) Mechanism: Dual GLP-1 and GIP receptor agonist — adds a second pathway that appears to produce greater weight loss than GLP-1 alone
Clinical data: SURMOUNT trials showed average weight loss of 20.9% at 72 weeks at the 15mg/week dose. More than any other FDA-approved weight loss medication in history.
Approved doses: 2.5mg/week (starting) → 15mg/week (maintenance)
Timeline: Similar to semaglutide; full effect at 12–15 months
Side effects: Comparable to semaglutide — nausea, vomiting, diarrhea during titration
### Liraglutide (Saxenda) — Largely Superseded Mechanism: GLP-1 receptor agonist, daily injection (vs weekly for sema/tirze)
Clinical data: ~8% weight loss at 56 weeks — significantly less than semaglutide or tirzepatide
Status: Still available but rarely prescribed for weight loss given better options. Notable use case: when weekly injectables aren't tolerated.
### Phentermine/Topiramate (Qsymia) — Oral Option Mechanism: Sympathomimetic + anticonvulsant — suppresses appetite through different pathway than GLP-1
Clinical data: ~9% weight loss at 56 weeks for the high-dose combination
Advantages: Oral (no injections), lower cost than GLP-1 agents, faster effect onset
Disadvantages: More side effects (heart rate, cognitive effects from topiramate, potential for dependence), not for patients with cardiovascular disease or history of substance use issues
### Naltrexone/Bupropion (Contrave) — Oral Option Mechanism: Dopamine/norepinephrine reuptake inhibition + opioid antagonism — targets reward pathways
Clinical data: ~5–7% weight loss, modest compared to GLP-1 agents
Status: Often used in combination with GLP-1 for patients who've plateaued, or as a bridge when GLP-1 agents aren't accessible
Head-to-Head: Semaglutide vs. Tirzepatide
The SURMOUNT-5 trial directly compared the two at maximum tolerated doses. Key results:
| Metric | Semaglutide 2.4mg | Tirzepatide 15mg | |---|---|---| | Mean weight loss | 13.7% | 20.2% | | ≥5% weight loss | 78% | 93% | | ≥20% weight loss | 16% | 40% | | Nausea rate | Similar | Similar |
Takeaway: Tirzepatide produces meaningfully greater weight loss across the board. The question is access and cost — not clinical superiority.
Cost Comparison (2026)
| Medication | Brand-Name Cash Price | Compounded | |---|---|---| | Semaglutide | $1,100–$1,350/month | $149–$299/month | | Tirzepatide | $1,200–$1,500/month | $249–$399/month | | Liraglutide | $1,400+/month | Not commonly compounded | | Phentermine/Topiramate | $80–$200/month | N/A | | Naltrexone/Bupropion | $60–$150/month (generic) | N/A |
Compounded GLP-1 options from verified 503B pharmacies make the most effective medications accessible at a fraction of brand cost.
How to Choose
Start with tirzepatide if: - Maximum weight loss outcome is the priority - You've tried semaglutide without sufficient results - You're starting fresh and want the most efficacious option
Start with semaglutide if: - You prefer a longer-established track record - Tirzepatide isn't available or accessible - Your physician has a strong clinical preference based on your profile
Consider oral options if: - You have needle aversion and can't overcome it - Cost is the primary constraint - GLP-1 options are contraindicated for you
At Marrow, your physician reviews your health history, prior weight loss attempts, and goals to recommend the right starting point.
[Start your intake →](/start)
Frequently Asked Questions
Is tirzepatide better than semaglutide for weight loss?
By clinical trial data, yes — tirzepatide produces about 5–7% more total weight loss on average, and a much higher percentage of patients achieve ≥20% weight loss. SURMOUNT-5 (the head-to-head trial) confirmed tirzepatide's superiority. Both are excellent medications; tirzepatide is more effective.
Can I switch from semaglutide to tirzepatide?
Yes — your physician can transition you between GLP-1 agents. There's typically a washout or transition period. Patients who've plateaued on semaglutide often see renewed weight loss after switching to tirzepatide.
Do GLP-1 medications work for everyone?
Response varies. Most patients lose 10–20%+ of body weight, but 10–15% of patients are 'poor responders' with <5% weight loss even at maximum dose. Genetic factors, gut microbiome, and metabolic health all influence response.
Do you regain weight after stopping GLP-1 medications?
Most people regain a significant portion of lost weight after stopping GLP-1 agents, because the medications treat the biological drivers of excess weight (appetite dysregulation, insulin resistance) rather than the weight itself. Lifestyle changes during treatment improve long-term outcomes but most patients benefit from long-term use.
Get our free Body Composition Guide
Protein protocols, workout structure, sleep optimization, and the supplement stack that actually works.
Get our free Body Composition Guide →
